{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T23:30:16Z","timestamp":1749511816302},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1694","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved perfluorohexyloctane ophthalmic solution (Miebo \u2013 Bausch+Lomb) for treatment of dry eye disease. Available only by prescription, Miebo is the first ophthalmic product to be approved in the US that specifically targets tear evaporation caused by meibomian gland dysfunction. An ophthalmic solution with a similar name, Miebo Tears (Vista), which contains 0.6% propylene glycol, is available over the counter for dry eye relief.<\/jats:p>","DOI":"10.58347\/tml.2024.1694c","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T18:24:23Z","timestamp":1704824663000},"page":"13-14","source":"Crossref","is-referenced-by-count":1,"title":["Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,1,22]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T18:24:23Z","timestamp":1704824663000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1694c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":0,"journal-issue":{"issue":"1694","published-online":{"date-parts":[[2024,1,22]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1694c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}